New cancer antibody enters human testing

NCT ID NCT05378425

First seen Nov 01, 2025 · Last updated Apr 21, 2026 · Updated 22 times

Summary

This is the first study in people testing a new antibody drug called NTX-1088, which targets a protein found on many cancer cells. The trial will test the safety of NTX-1088 given alone and in combination with an existing immunotherapy drug (pembrolizumab) in 90 patients with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find safe doses and understand how the body handles the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

    Contact

  • Hadassah Medical Center

    RECRUITING

    Jerusalem, 9574425, Israel

    Contact

  • Maria Skłodowska-Curie National Research Institute of Oncology

    NOT_YET_RECRUITING

    Warsaw, Poland

    Contact

  • Ochsner Clinic Foundation

    RECRUITING

    New Orleans, Louisiana, 70121, United States

    Contact

  • Sheba Medical Center

    RECRUITING

    Ramat Gan, 5262131, Israel

    Contact

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.